Charles Cherington

CIK: 0001448698

Transaction Breakdown

Open Market Buys (P)18 (62.1%)

High conviction signal

Open Market Sales (S)10 (34.5%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (3.4%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ERNA

Ernexa Therapeutics Inc.

10% Owner

Discretionary Trading P&L

Holdings

Transaction History (29 total)

ERNA
Ernexa Therapeutics Inc.
Feb 10, 2026
Purchase(P)
Direct
4M shares at avg. $0.50$2.0M
ERNA
Ernexa Therapeutics Inc.
Jun 9, 2025
Purchase(P)
Direct
21.2M shares at avg. $0.10$2.2M
ERNA
Eterna Therapeutics Inc.
Apr 2, 2025
Purchase(P)
Direct
3.8M shares at avg. $0.10$394K
ERNA
Eterna Therapeutics Inc.
Oct 29, 2024
Sale(S)
Warrants (right to buy)
Direct
3.1M shares-
ERNA
Eterna Therapeutics Inc.
Oct 29, 2024
Sale(S)
Warrants (right to buy)
Direct
2.5M shares-
ERNA
Eterna Therapeutics Inc.
Oct 29, 2024
Sale(S)
Warrants (right to buy)
Direct
523.5K shares-
ERNA
Eterna Therapeutics Inc.
Oct 29, 2024
Sale(S)
6.0% Senior Convertible Promissory Notes due 2028
Direct
0 shares-
ERNA
Eterna Therapeutics Inc.
Oct 29, 2024
Sale(S)
12.0% Senior Convertible Notes due December 12, 2028
Direct
0 shares-
ERNA
Eterna Therapeutics Inc.
Oct 29, 2024
Purchase(P)
Direct
1.2M shares-
ERNA
Eterna Therapeutics Inc.
Oct 29, 2024
Purchase(P)
Direct
5.4M shares-
ERNA
Eterna Therapeutics Inc.
Oct 29, 2024
Purchase(P)
Direct
1.6M shares-
ERNA
Eterna Therapeutics Inc.
Oct 29, 2024
Conversion(C)
Direct
2.8M shares at avg. $0.50$1.4M
ERNA
Eterna Therapeutics Inc.
Oct 29, 2024
Purchase(P)
Direct
261.8K shares-
ERNA
Eterna Therapeutics Inc.
Oct 29, 2024
Purchase(P)
Direct
4.8M shares-
ERNA
Ernexa Therapeutics Inc.
Sep 24, 2024
Sale(S)
12.0% Senior Convertible Notes due December 12, 2028
Direct
0 shares-
ERNA
Ernexa Therapeutics Inc.
Sep 24, 2024
Purchase(P)
Direct
4.8M shares-
ERNA
Ernexa Therapeutics Inc.
Sep 24, 2024
Purchase(P)
Direct
1.2M shares-
ERNA
Ernexa Therapeutics Inc.
Sep 24, 2024
Purchase(P)
Direct
5.4M shares-
ERNA
Ernexa Therapeutics Inc.
Sep 24, 2024
Purchase(P)
Direct
1.6M shares-
ERNA
Ernexa Therapeutics Inc.
Sep 24, 2024
Purchase(P)
Direct
261.8K shares-
ERNA
Ernexa Therapeutics Inc.
Sep 24, 2024
Sale(S)
6.0% Senior Convertible Promissory Notes due 2028
Direct
0 shares-
ERNA
Ernexa Therapeutics Inc.
Sep 24, 2024
Sale(S)
Warrants (right to buy)
Direct
523.5K shares-
ERNA
Ernexa Therapeutics Inc.
Sep 24, 2024
Sale(S)
Warrants (right to buy)
Direct
2.5M shares-
ERNA
Ernexa Therapeutics Inc.
Sep 24, 2024
Sale(S)
Warrants (right to buy)
Direct
3.1M shares-
ERNA
Eterna Therapeutics Inc.
Sep 24, 2024
Purchase(P)
12.0% Senior Convertible Notes due September 24, 2025
Direct
0 shares at avg. $1368626.00-

		Type	Shares	Price		Ownership
Feb 10, 2026	ERNA Ernexa Therapeutics Inc.	Purchase(P)	4,000,000	$0.50	$2,000,000	Direct
Jun 9, 2025	ERNA Ernexa Therapeutics Inc.	Purchase(P)	21,241,163	$0.10	$2,221,826	Direct
Apr 2, 2025	ERNA Eterna Therapeutics Inc.	Purchase(P)	3,768,397	$0.10	$394,174	Direct
Oct 29, 2024	ERNA Eterna Therapeutics Inc.	Sale(S) Warrants (right to buy)	3,125,976	-	-	Direct
Oct 29, 2024	ERNA Eterna Therapeutics Inc.	Sale(S) Warrants (right to buy)	2,475,524	-	-	Direct
Oct 29, 2024	ERNA Eterna Therapeutics Inc.	Sale(S) Warrants (right to buy)	523,512	-	-	Direct
Oct 29, 2024	ERNA Eterna Therapeutics Inc.	Sale(S) 6.0% Senior Convertible Promissory Notes due 2028	0	-	-	Direct
Oct 29, 2024	ERNA Eterna Therapeutics Inc.	Sale(S) 12.0% Senior Convertible Notes due December 12, 2028	0	-	-	Direct
Oct 29, 2024	ERNA Eterna Therapeutics Inc.	Purchase(P)	1,237,762	-	$0	Direct
Oct 29, 2024	ERNA Eterna Therapeutics Inc.	Purchase(P)	5,420,823	-	$0	Direct
Oct 29, 2024	ERNA Eterna Therapeutics Inc.	Purchase(P)	1,562,988	-	$0	Direct
Oct 29, 2024	ERNA Eterna Therapeutics Inc.	Conversion(C)	2,819,546	$0.50	$1,409,773	Direct
Oct 29, 2024	ERNA Eterna Therapeutics Inc.	Purchase(P)	261,756	-	$0	Direct
Oct 29, 2024	ERNA Eterna Therapeutics Inc.	Purchase(P)	4,768,783	-	$0	Direct
Sep 24, 2024	ERNA Ernexa Therapeutics Inc.	Sale(S) 12.0% Senior Convertible Notes due December 12, 2028	0	-	-	Direct
Sep 24, 2024	ERNA Ernexa Therapeutics Inc.	Purchase(P)	4,768,783	-	-	Direct
Sep 24, 2024	ERNA Ernexa Therapeutics Inc.	Purchase(P)	1,237,762	-	-	Direct
Sep 24, 2024	ERNA Ernexa Therapeutics Inc.	Purchase(P)	5,420,823	-	-	Direct
Sep 24, 2024	ERNA Ernexa Therapeutics Inc.	Purchase(P)	1,562,988	-	-	Direct
Sep 24, 2024	ERNA Ernexa Therapeutics Inc.	Purchase(P)	261,756	-	-	Direct
Sep 24, 2024	ERNA Ernexa Therapeutics Inc.	Sale(S) 6.0% Senior Convertible Promissory Notes due 2028	0	-	-	Direct
Sep 24, 2024	ERNA Ernexa Therapeutics Inc.	Sale(S) Warrants (right to buy)	523,512	-	-	Direct
Sep 24, 2024	ERNA Ernexa Therapeutics Inc.	Sale(S) Warrants (right to buy)	2,475,524	-	-	Direct
Sep 24, 2024	ERNA Ernexa Therapeutics Inc.	Sale(S) Warrants (right to buy)	3,125,976	-	-	Direct
Sep 24, 2024	ERNA Eterna Therapeutics Inc.	Purchase(P) 12.0% Senior Convertible Notes due September 24, 2025	0	$1368626.00	-	Direct

1-25 of 29 transactions

About Cherington Charles

Cherington Charles (SEC CIK 0001448698) files insider reports with the SEC as 10% Owner of Ernexa Therapeutics Inc. (ERNA).

Signal8 holds 5 ownership filings by Cherington Charles, all Form 4s, filed between Nov 5, 2024 and Feb 17, 2026. Those filings report 29 transactions, from Sep 23, 2024 to Feb 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Cherington Charles's filings is in BOSTON, MA.

Recent filings by Cherington Charles

Feb 10, 2026: Open-market purchase of ERNA shares (Form 4, code P).
Jun 9, 2025: Open-market purchase of ERNA shares (Form 4, code P).
Apr 2, 2025: Open-market purchase of ERNA shares (Form 4, code P).
Oct 29, 2024: Open-market sales of ERNA derivative securities (5 lines, Form 4, code S).
Oct 29, 2024: Open-market purchases of ERNA shares (3 lines, Form 4, code P).

Other insiders filing for Ernexa Therapeutics Inc. (ERNA)

Spiegel Robert J., Director
Bristol James Arthur, Director
Cicala Peter, Director
Polinsky David, Director
Wexler William A., Director
Ratner Elena, Director

How to read Form 4 transaction codes